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ABSTRACT
OBJECTIVE: To review studies on the readability of package leaflets of 
medicinal products for human use.
METHODS: We conducted a systematic literature review between 2008 and 
2013 using the keywords “Readability and Package Leaflet” and “Readability 
and Package Insert” in the academic search engine Biblioteca do Conhecimento 
Online, comprising different bibliographic resources/databases. The preferred 
reporting items for systematic reviews and meta-analyses criteria were applied 
to prepare the draft of the report. Quantitative and qualitative original studies 
were included. Opinion or review studies not written in English, Portuguese, 
Italian, French, or Spanish were excluded.
RESULTS: We identified 202 studies, of which 180 were excluded and 22 
were enrolled [two enrolling healthcare professionals, 10 enrolling other 
type of participants (including patients), three focused on adverse reactions, 
and 7 descriptive studies]. The package leaflets presented various readability 
problems, such as complex and difficult to understand texts, small font 
size, or few illustrations. The main methods to assess the readability of the 
package leaflet were usability tests or legibility formulae. Limitations with 
these methods included reduced number of participants; lack of readability 
formulas specifically validated for specific languages (e.g., Portuguese); and 
absence of an assessment on patients literacy, health knowledge, cognitive 
skills, levels of satisfaction, and opinions.
CONCLUSIONS: Overall, the package leaflets presented various readability 
problems. In this review, some methodological limitations were identified, 
including the participation of a limited number of patients and healthcare 
professionals, the absence of prior assessments of participant literacy, humor 
or sense of satisfaction, or the predominance of studies not based on role-
plays about the use of medicines. These limitations should be avoided in 
future studies and be considered when interpreting the results.
DESCRIPTORS: Medicine Package Inserts. Comprehension. 
Consumer Health Information. Review.
Review DOI:10.1590/S0034-8910.2015049005559
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The readability of the package leaflets is an essential issue 
for the safety and rational use of medicines after they are 
prescribed or dispensed in pharmacies. Patients may inde-
pendently consult the package leaflets to clarify their doubts, 
such as information on medicine administration.21,22,25
The inclusion of package leaflets inside all medicine 
packages is obligatory in the European Union.a In 
RESUMO
OBJECTIVO: Analisar a literatura sobre legibilidade das bulas dos 
medicamentos para uso humano.
MÉTODOS: Estudo de revisão sistemática, utilizando as palavras-chave 
“Readability and Package Leaflet” e “Readability and Package Insert”e a 
ferramenta de busca académica b-on, que contém diferentes bases bibliográficas. 
O período analisado foi entre 2008 e 2013. Foram aplicados os critérios PRISMA 
para redigir o relatório da revisão. Foram incluídos artigos originais de pesquisa 
quantitativa ou qualitativa. Os critérios de exclusão foram: artigos de opinião 
ou de revisão, ou escritos numa língua diferente do inglês, português, italiano, 
francês ou espanhol.
RESULTADOS: Foram identificados 202 trabalhos, dos quais 180 foram 
excluídos e 22 selecionados para análise: dois com profissionais de saúde, 
10 com pacientes, três sobre reações adversas e sete descritivos. As bulas 
apresentaram diversos problemas de legibilidade, entre os quais: textos 
insuficientemente claros e simples, utilização de tamanhos de letra pequenos 
e número reduzido de ilustrações. Os principais métodos utilizados para 
avaliar a legibilidade das bulas foram as fórmulas e os testes de legibilidade/
usabilidade. Entre as limitações metodológicas, foram identificados aspetos 
como o recurso a amostras pequenas, a inexistência de fórmulas de legibilidade 
específicas para a língua em causa, e.g., português, e a realização de testes de 
compreensão em grupos de pacientes sem avaliação prévia da literacia, dos 
conhecimentos específicos na área da saúde, das capacidades cognitivas, ou 
do grau de satisfação dos participantes.
CONCLUSõES: Em geral, as bulas apresentaram diversos problemas de 
legibilidade. Adicionalmente, nesta revisão foram identificadas algumas 
limitações metodológicas nos estudos revistos (e.g. a participação de um número 
reduzido de pacientes e profissionais de saúde, a ausência da avaliação prévia da 
literacia, do humor ou satisfação dos participantes ou o predomínio de estudos 
não baseados em encenações sobre o uso de medicamentos) que deverão ser 
consideradas na apreciação dos resultados e contornadas em estudos futuros.
DESCRIPTORES: Bulas de Medicamentos. Compreensão. Informação de 
Saúde ao Consumidor. Revisão.
INTRODUCTION
accordance with regulations,29 the package leaflets 
must be organized in pre-defined sectionsb and written 
in a clear and comprehensible way.c
The European template on the content of the package 
leaflets is the Quality Review of Documents (QRD).b 
This template was updated several times since the 
first version was published (1996).29 According to the 
a European Parliament and the Council. Directive 2001/83/EC: community code relating to medicinal products for human use. Brussels; 6 Nov 2001 
[cited 2013 Aug 12]. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_en.pdf
b European Medicine Agency. Quality review of documents human product-information annotated template. Version 9. London; 2013 [cited 2013 
Oct 13]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000134.jspp
c European Medicine Agency. Guideline on the readability of the labelling and package leaflet of medicinal products for human use. London; 
2009 [cited 2013 Aug 12]. Available from: http://ec.europa.eu/health/files/eudralex/vol-2/c/2009_01_12_readability_guideline_final_en.pdf
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9th version of QRD,b the package leaflets should be 
organized as follows:
1. What X (X = name of the medicine) is and its 
indicated use;
2. What you need to know before you <take> <use> X;
3. How to <take> <use> X;
4. Possible side effects;
5. How to store X;
6. Contents of the pack and other information.
The results of legibility and usabilityc tests are used to 
prove the simplicity, clarity, and comprehensibility of 
the information on the package leaflets for the medi-
cine users.21,25 The guideline on the readability of the 
labeling and package leaflet of medicinal products for 
human use (European commission, 1998) was the first 
on this issue in Europe and is used by the European 
Medicine Agency.c According to the general princi-
ples of these guideline,a,c a questionnaire should be 
administered to at least 20 patients, preferentially 
from the population for which the medicinal product is 
intended. Healthcare professionals should not partic-
ipate in legibility testsc,d so as to not bias the results. 
In contrast, it is advisable that geriatric and less profi-
cient patients participate in these tests because these 
subjects usually present more difficulties in reading 
and interpreting documents.14 The main topics of the 
package leaflets (indications or contraindications) are 
commonly selected to be examined.c The aims of these 
tests are to identify problems with the location and 
comprehension of the information on package leaflets, 
and if necessary, to optimize the package leafletsc and 
repeat the tests (retests).21,25 The package leaflets are 
considered acceptable when the participants obtain at 
least 90.0% of answers.d
Although the medical authorities of each European 
country evaluate the legibility of package leaflets before 
their approval,2 sometimes these documents are not 
adequately understood [e.g., dosage or adverse drug 
reactions (ADR)]. This is particularly bad for low-lit-
erate patients.21,25
The objective of the present study was to review studies 
on the readability of package leaflets of medicinal prod-
ucts for human use.
METHODS
Systematic review. The preferred reporting items for 
systematic reviews and meta-analyses (PRISMA) 
criteria were used to organize the report on the selected 
studies.e The studies were conducted between January 
1, 2008 and February 24, 2013 (five years and two 
months), with the aim of including recent investigations 
and pharmaceutical regulatory updates.c
The study keywords were “readability and package 
leaflet” or “readability and package insert” sepa-
rated by the Boolean operator “and”. The selection 
of both designations followed from the fact that the 
designation “package leaflet” is more common in 
European countriesc,d and “package insert” is used 
outside Europe.20,f
The search was performed using the academic 
search engine, Biblioteca do Conhecimento Online 
(b-on).g This tool allows access to thousands of scien-
tific journals and concurrent searches in different 
databases and bibliographic databases, including 
BioMed Central,h BioOne,i Bioline International,j 
Directory of Open Access Journals,k Medical Literature 
Analysis and Retrieval System Online (Medline),l 
United States National Library of Medicine National 
Institutes of Health (PubMed),m Scientific Electronic 
Library Online (Scielo Global),n Elseviero and 
d The Heads of Medicines Agencies, Co-ordination Group for Mutual Recognition and Decentralised Procedures-Human. Position paper 
on user testing of package leaflet – consultation with target patient groups. 2011 [cited 2013 Oct 27]. Available from: http://www.hma.eu/
fileadmin/dateien/Human_Medicines/CMD_h_/procedural_guidance/Consulation_PatientsGroups/CMDh_234_2011.pdf
e Critérios Prisma - Transparent reporting of systematic reviews and meta-analysis; 2013 [cited 2013 Aug 16]. Available from: http://www.
prisma-statement.org/
f Australian Governament, Department of Health and Ageing, Therapeutic Good Administration. Mechanisms to maintain the currency of 
approved Product Information (PI) and Consumer Medicine Information (CMI): public consultation paper. Version 2013 [cited 2013 Aug 12]. 
Available from: https://www.google.pt/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&ved=0CDsQFjAB&url=http%3A%2F%2Fwww.tga.gov.
au%2Fword%2Fconsult%2Fconsult-opr-currency-pi-cmi-130513.docx&ei=fwdtUvenA_Op7Ab7ooHoDg&usg=AFQjCNHhjdYSrmN2s0muw
VNMjwVS6UEu0w&sig2=Jtp7FfAdBJYD2oaORlX4zg&bvm=bv.55123115,d.ZG4&cad=rjtg
g B On: Biblioteca do conhecimento online. Lisboa: Fundação para a Computação Nacional; 2013 [cited 2013 Aug 12]. Available from: 
http://www.b-on.pt/
h BMC: BioMed Central the open access publisher; 2014 [cited 2014 Dec 2]. Available from: http://www.biomedcentral.com
i BioOne online journals; 2014 [cited 2014 Dec 2]. Available from: http://www.bioone.org/
j Bioline International; 2014 [cited 2014 Dec 2]. Available from: http://www.bioline.org.br/
k DOAJ: Directory of Open Access Journals; 2014 [cited 2014 Dec 2]. Available from: http://doaj.org/
l MEDLINE: Medical Literature Analysis and Retrieval System Online. Bethesda (MD): US National Library of Medicine; [s.d.]. [cited 2014 Jul 
28]. Available from: http://www.ncbi.nlm.nih.gov/IEB/ToolBox/SDKDOCS/MEDLINE.HTML
m PubMed: the bibliographic database of the United States National Library of Medicine National Institutes of Health [Internet]. Bethesda 
(MD): National Library of Medicine. [1946] - [cited 2014 Jul 27]. Available from: http://www.ncbi.nlm.nih.gov/pubmed
n SciELO: Scientific Electronic Library Online [Internet]. São Paulo (BR): Bireme/OPS/FAPESP/CNPq. [1998]. [cited 2014 Jul 28]. Available 
from: http://www.scielo.org/php/index.php?lang=en
o Elsevier; 2014 [cited 2014 Dec 2]. Available from: http://www.elsevier.com/
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SpringerLink.p Moreover, two complementary searches 
were performed. One used PubMed to confirm the 
existence of additional results, and the other used 
the Cochrane Collaboration Reviewsq to confirm the 
existence of other reviews on this topic, which contrib-
uted to validate the interest and relevance of this review. 
All the review results are properly archived and avail-
able for future consultations. The inclusion and exclu-
sion criteria are described in Table 1.
The repeated references were automatically identi-
fied using EndNoteWeb (a management references 
program).r The main findings of the selected studies 
were summarized and organized into a tabular format 
(objectives, methods, results, and conclusions). The 
selected studies were divided into the following two 
categories. The first category comprised exploratory 
studies (studies with the participation of health profes-
sionals or patients), and the second was descriptive 
studies or studies involving non-enrolling participants 
(studies using legibility formulas or investigating the 
linguistic characteristics of texts). In particular, the 
studies on the readability of ADR were described and 
analyzed because of the importance of this issue for 
patient safety.29 The selected studies were classified 
as follows:
1. Exploratory studies specifically enrolling health 
professionals;
2. Exploratory studies enrolling patients (or potential 
users of medicines), such as studies on comprehen-
sion of ADR (readability/usability tests) by patients;
3. Descriptive studies (studies using non-enrolled 
participants, i.e., all the non-experimental studies) 
on the readability of package leaflets, including 
studies that evaluate the number of words, length 
of phrases, or letter type.
Overall, the selected studies were comparatively 
analyzed. The main findings, potential limitations, 
and the opportunity for future work were evaluated 
and registered.
RESULTS AND DISCUSSION
Twenty-two studies out of the 202 were selected and 
comprised 16 full papers, three brief communications, 
and three indexed abstracts. The number of included 
and excluded studies are presented in Table 2 in addition 
to different keywords and search tools. The flowchart 
is organized using the PRISMAf criteria, representing 
the exclusion reasons (Figure). None of the studies 
on the topics under review was found in the database 
of Cochrane Collaboration Reviews, confirming the 
interest in this review.
The main aspects (objectives, methods, results, and 
conclusions) of the selected studies are summarized 
in Table 3. The 22 selected studies were distributed as 
follows: two in Group A (exploratory studies enrolling 
health professionals), 12 in Group B (exploratory studies 
enrolling patients or potential patients who will use the 
medicines), and eight in Group C (descriptive studies).
Overall, few studies on the readability of the package 
leaflets were identified compared to a search in PubMed 
using the search term, “patient information”, which 
identified 6,357 search results on October 13, 2013.
Exploratory studies enrolling health professionals, 
patients or potential users of medicines
In the two exploratory studies (group A),5,22 wherein 
healthcare professionals (physicians or pharmacists) 
participated, it was reported that the healthcare profes-
sionals were satisfied with the information in the leaf-
lets. They considered the information in the package 
leaflets more important than did the actual patients 
(or potential patients) who required the medicines. 
In contrast, the patients (or potential patients) who 
would be using the medicines expressed their prefer-
ences for receiving personal explanations on the use 
of medicines during consultations. One reason for this 
was due to the high prevalence of technical terms in 
the package leaflets. Only two studies with healthcare 
professionals were identified in this revision, although 
these studies were important to validate the optimized 
package leaflets.5,22
From the twelve exploratory studies with patients (or 
potential patients) receiving medicines (group B), ten 
were conducted to evaluate participant comprehen-
sion (usability and/or legibility tests,1,2,6,8,11,12,19,21,25,26 or 
studies to specifically evaluate participant comprehen-
sion of the manner in which ADR were presented.18,17
The main problems identified in these 10 studies were 
patient (or potential patient) comprehension issues 
as some topics were poorly understood;2,11,19,25,26 too 
complex texts, indicating the necessity of optimizing 
and simplifying the package leaflets;1,11,12,21 and package 
leaflets not properly adapted for the low-literate patients, 
indicating the need to use simpler language.1,6,8,19
The majority of the reviewed readability studies used 
package leaflets of specific medicines, including silde-
nafil, clozapine, acetaminophen, and diclofenac.1,6,19,26 
It is likely that these package leaflets were selected for 
p SpringerLink; 2014 [cited 2014 Dec 2]. Available from: http://link.springer.com/
q Cochrane collaboration reviews; 2014 [cited 2014 Dec 2]. Available from: http://www.cochrane.org/cochrane-reviews
r EndnoteWeb. New York: Thomson Reuters; 2013 [cited 2013 Aug 12]. Available from: https://www.myendnoteweb.com/EndNoteWeb.html?S
ID=P2g6anKIJyF54XPliP4&returnCode=ROUTER.Success&SrcApp=CR&Init=Yes
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the following reasons: the straight therapeutic indices 
of some medicines such as clozapine,1 over-the-
counter medicines (no prescription necessary), such 
as diclofenac and acetaminophen, and highly utilized 
medicines such as acetaminophen.6,19 The package leaf-
lets of these medicines are more likely to be consulted. 
Therefore, it is difficult to generalize about or extend 
conclusions of these studies to the package leaflets 
of medicines with different active ingredients. The 
study on the automatic simplification of the technical 
terms was considered particularly relevant because an 
automatic methodology was used to simplify diverse 
package leaflets at the same time. In this study, an 
informatics tool was used, and the technical terms of 
the package leaflets were identified. More common and 
equivalent terms were then found in pre-defined lexical 
databases and finally, the original terms were automat-
ically replaced by the more common terms.11
Diverse limitations were identified in these 
studies1,2,6,8,11,12,19,21,25,26 and were categorized as 
follows: high diversity of methods, limited number 
of participants, lack of certain assessments (such as 
the evaluation of participant literacy, humor, cogni-
tive state, and satisfaction), lack of multicenter 
or longitudinal studies, lack of studies on specific 
topics such as contra-indications and precautions, 
study of the package leaflets from a limited number 
of medicines and active ingredients,1,6,19,26 and lack 
of pictograms (useful for low-literate patients) or 
Table 1. Inclusion and exclusion criteria of studies on the package leaflets of medicinal products for human use.
Criteria
Inclusion Exclusion
Studies or abstracts Studies or abstracts
Original Out of the research period
Quantitative Repeated
Qualitative Review or opinion
Exploratory Not directly related with the research topicaa
Descriptive Other languagesb
a Studies not specifically related with the package leaflets (e.g., studies on the readability of medicines labels) or medicines 
(e.g., studies on the readability of the package leaflets of medical devices or information on disease management).
b Original documents in languages other than English, Portuguese, Italian, French, or Spanish.
Table 2. Number of studies searched, included and excluded, pear search tools, keywords, and reasons for exclusion; period: 
January 1, 2008 February 24, 2013.
Search tool Keywords Total Repeated Excluded/Reasons Selecteda
PubMed “Readability and 
Package Insert”
17 1 14
10 - out of the period
1 - other languageb
1 - opinion studies
2 - other topics
2
“Readability and 
Package Leaflet”
67 6 58
34 - out of the period
2 - other language
1 - opinion studies
5 - other topics
16 - other productsc
3
B-on “Readability and 
Package Insert”
59 20 32
28 - out of period
1 - other language
3 - other products
7
“Readability and 
Package Leaflet”
59 3 46
29 - out of period
4 - opinion studies
3 - other topics
10 - other productsc
10
Total 202 30 150 22
PubMed: United States National Library of Medicine National Institutes of Health; b-on: Biblioteca do Conhecimento Online
a Selected studies = Total - Repeated - Excluded.
b Original documents in languages other than English, Portuguese, Italian, French, or Spanish.
c Studies on the readability of the package leaflets of other products than medications.
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other illustrations.8,24 A few authors reported that 
the study limitations were contrary to good clin-
ical practices, increasing the difficulty of precisely 
analyzing the results.
Studies on comprehension of adverse drug reactions
The presentation of ADR was particularly rele-
vant in two studies (group B) because the patient 
comprehension of ADR strongly depended on the 
way ADR were presented.18,17 ADR were described 
in different manners in these studies. These ADR 
were described using qualitative descriptors (very 
common ADR) or quantitative descriptors (adverse 
reactions with a likelihood of 1.0%-10.0%).18 
Further, it was found that patients preferred numer-
ically expressed ADR (using absolute frequen-
cies)18,17 and considered the use of fractions (≥ 
1/100) to be difficult to understand when the ADR 
frequency3,17,18,27 was presented in this manner.
In general, the section of the package leaflets on 
ADR was compliant with the recommendations of 
the QRD.3,17,18,29,b According to the requirements of 
the QRD template, ADR are presented in an ordered 
list of values (from the more to less frequent ADR). 
For example, a “common” ADR may affect up to 
1 in 10 people, and “uncommon” ADR may affect 
up to 1 in 100 people.29 
The number of studies specifically concerned with 
the most appropriate way to present ADR and the 
number of participants enrolled in these studies 
were limited.
Descriptive studies
The eight descriptive studies3,4,13,23,24,27,28,30 (or studies 
with non-enrolled participants) on the usability of the 
package leaflets (group C) focused on the following 
aspects:3,4,13,23,24,27,28,30 (i) use of legibility formulas, 
such as Flesch-Kincaid or Fry to calculate values 
on the association between the linguistic charac-
teristic of texts and the education level of patients 
(linguistic metrics),4,23,24,27,28,30 (ii) identification of 
specific linguistic characteristics (e.g., number of 
difficult words or phrases) to obtain indirect indica-
tors on the proper readability of texts;3 and (iii) eval-
uation of graphical aspects that facilitate the under-
standing of information (e.g., letter size or presence 
of illustrations).24,27,30
Overall, the application of the descriptive methodolo-
gies confirmed a low readability of the package leaf-
lets and the need to simplify the texts. The factors that 
decrease the readability of the package leaflets were 
evident in some studies and included the following: too 
complex texts (e.g., some package leaflets were clas-
sified as appropriate for readers with 10 or more years 
Total of identified studies
202
Studies out of the time period
101
Repeated studies
30
Opinion or review studies
6
Studies in other languagesa
4
Analyzed studies
22
Studies not specifically related with 
package leaflets
10b
Studies related with other products or 
situations
29c
Figure. Flowchart: exclusion reasons for the researched studies.
a Languages: one study in Norwegian and three studies in 
German.
b Studies on the readability of medication informative 
materials, e.g., external packages or labels.
c Studies on the readability of the package leaflets of other 
products (non-medication), including food, chemicals or 
herbal products, medical devices, or information on the 
risk of abortion, clinical trials or disease management.
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Table 3. Informative summary of the selected studies on the readability of package leaflets of medicinal products and identified 
in search tools; period: January 1, 2008‒February 24, 2013.
Reference Objective(s) Methods Results Conclusion
A. Exploratory studies with the participation of health professionals
Cavaco et al,5 2012 
(resume)
Optimization of 
package leaflets
2 groups: potential 
users and physicians
An original and 
optimized package 
leaflet (diclofenac) 
was tested 
Questionnaires
Opinion on technical 
terms (Likert scale)
42 potential users
42 physicians
Satisfaction on the 
original package 
leaflet: 0.0% good; 
10.0% satisfactory
Satisfaction on the 
technical terms 
(optimized package 
leaflet): 20.0% good; 
65.0% satisfactory
Lexical modifications 
produced favorable 
results
March J et al,22 2009 Opinion study Interviews
Flesch formula (25 
package leaflets)
Participants: 
(40) patients, (6) 
physicians, (11) 
pharmacists and (13) 
from associations of 
patients
Health professionals 
attributed more 
importance to the 
package leaflets 
in comparison to 
patients
More difficult issues: 
dosage, ADR and 
contra-indications
Flesch index: high
The real needs of 
health professionals 
and patients should 
be considered during 
the development of 
package leaflets
The patients preferred 
to receive the direct 
opinion of health 
professionals
B. 1. Exploratory studies with the participation of potential users of medicines: studies on patients’ comprehension of drug 
adverse reactions
Knapp et al,17 2010 
(brief communication)
Comprehension of 
ADR
ADR presented in 
different formats
Opinion on the 
preferred format
Imaginary scenario: 
opinion on the 
probability of ADR 
(if taking tamoxifen)
134 participants
The absolute 
frequencies (e.g., 48 
persons in each 100) 
were considered more 
precise/clear than the 
interval of frequencies 
(e.g., affect more than 
one person in each 10)
The use of absolute 
frequencies to present 
ADR demonstrated to 
be more appropriate
Knapp P et al,18 2009 Presentation of ADR Classification of ADR: 
using verbal (e.g., 
rare) or numerical 
(e.g., 1 in 10) 
descriptors, or both
Imaginary scenario: 
estimate the risk of 4 
ADR and satisfaction 
(if taking tamoxifen)
187 Participants
Absolute frequencies 
were more favorable
Future studies are 
advisable
B. 2. Exploratory studies with the participation of users or potential users of medicines: comprehension studies
Symonds T et al,26 
2010
Participant 
comprehension 
(sildenafil package 
leaflet)
Two groups of 
participants: 
consultation versus 
hypothetical auto-
administration
Questionnaire
Blind study
Participants: 113 
healthy men and 70 
with health problems 
(e.g., prostatic 
hypertrophy)
The results between 
both groups were 
concordant in more 
than 73.9%
It may be necessary 
to optimize the 
indications
Continue
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Continuation
Shiffman S et al,25 
2011
Participant 
comprehension 
(antidepressant 
information)
Materials: medication 
guide and package 
leaflet
Blind study
52 participants
A rare and dangerous 
ADR was identified by 
less than 20.0% of the 
participants
The information was 
not fully understood
Fuch et al,12 2010 Text length 
(evaluation)
Crossover study: 
1,105 participants 
(first phase), and 
1,057 participants 
(second phase)
Tested materials: 
5 original package 
leaflets + 5 optimized 
package leaflets
Questionnaire
The location of 
information was more 
difficult in the longer 
package leaflets
Average of words: 
2,505 (original) and 
2,002 (optimized)
The optimized 
package leaflets 
contained: less 
technical words 
(14 versus 86), less 
abbreviations (4 
versus 17), and shorter 
phrases (7 versus 29)
The length of the 
package leaflets 
was related 
with participant 
comprehension
The shorter package 
leaflets (1,500 words) 
were more adequate
Lee et al,19 2012
(abstract)
Legibility tests 
(comparison)
Two package 
leaflets: over the 
counter medicines 
(acetaminophen)
Task: difficult words 
were underlined
Questionnaire: the 
questions were 
based on imaginary 
scenarios and related 
with the topics of the 
package leaflets
51 students
Better scores 
(73.0% to 80.0%) 
on: indications, 
dosage, pregnancy 
information, contra-
indications, and 
formulation
118 difficult words
Simplification of 
the package leaflets 
(friendlier package 
leaflets)
Maat HP et al,21 2010 Readability 
(evaluation)
3 original package 
leaflets + 3 optimized 
package leaflets 
(shorter phrases, 
simple text).
Questionnaire
154/164 potential 
users (original/modified 
package leaflets)
Optimized package 
leaflets: higher 
proportion of correct 
answers and topics 
located
The use of more 
narrow criteria to 
conceive the package 
leaflets is advisable
Brosnan S et al,1 2012 Readability 
(evaluation)
Patients with a 
prescription of 
clozapine
A validated tool was 
used to evaluate 
patients’ literacy
Optimized package 
leaflet: shorter phrases
Questionnaire on 
comprehension
40 patients
Literacy: 29 (72.5%) 
adequate, 11 low
Score of 
questionnaire: 72.5% 
(original package 
leaflet), 95.0% 
(optimized package 
leaflet)
It is important to 
consider patients’ 
literacy during the 
optimization of 
package leaflets
Cavaco A et al,6 2012
(Brief communication)
Literacy and 
readability
Clients of community 
pharmacies
A validated tool was 
used to evaluate 
participant literacy
Satisfaction with 
the readability of a 
diclofenac package 
leaflet (Likert scale)
53 participants (40.0% 
higher education, 
80.0% adequate 
literacy)
The average satisfaction 
was scored slightly 
below the neutrality
Less favorable issues: 
letter size, medical 
technical terms, and 
abbreviations
The readability issues 
were not related with 
the literacy level
Continue
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Continuation
Calamusa A et al,2 
2012
Quantifying 
knowledge
Questionnaire 
(drug store in large 
shopping areas)
Topics: medicine 
use and specific 
terminology
1,206 adults
 42.0% participants 
mistook 
contraindications for 
ADR
Lack of information 
on the long-term use 
of: laxatives (14.0%) 
or nasal decongestants 
(20.0%)
Advice on the use 
of medicines is 
recommended
Dowse R et al,8 2011 Participant 
comprehension
Low-literate 
participants
Package leaflet 
containing pictograms 
(anti-retroviral)
Interview: locate 
and explain the 
information, and give 
opinion on the use of 
pictograms
39 participants
Average 
(comprehension): 
60.0%
The zones of text 
with pictograms were 
better understood
All participants 
agreed with the use of 
pictograms
It is important to 
consider patient 
literacy in the 
development of 
package leaflets
The use of pictograms 
is likely to increase 
the intelligibility of 
package leaflets
Franck J et al,11 2011 Participant 
comprehension
2 package leaflets 
(oxazepam and 
tetracycline)
An informatics tool 
was used to optimize 
the package leaflets 
(brief explanation on 
medical terms)
Legibility tests (in 
accordance to the 
guideline of European 
Medicine Agency)
Participants: 10/20 
(original/ optimized 
package leaflets)
Participant literacy: 
homogeneous
Optimized package 
leaflets: more 
favorable results
The time and cost to 
optimize the package 
leaflets was reduced 
in consequence of 
using an informatics 
methodology
C. Descriptive studies: evaluation of the linguistic characteristics
Weiss SM et al,28 2010 Adequacy of texts Informative materials: 
approved/not approved 
by Food and Drug 
Administration
Formula of Simple 
Measure of 
Gobbledygook (SMOG)
Index of SMOG: 
above the 
recommended
Simplification of the 
package leaflets, 
especially for the low 
educated patients
Fuch J et al,13 2010 Information 
(characterization)
271 package leaflets
Quantification: 
number of words/
difficult words
Other topics 
identified: maximum 
daily dose, ADR, 
among other
Distribution of the 
information in the 
package leaflets: 
29.5% maximum daily 
dosage; 54.6% ADR, 
and 24.2% frequency 
of ADR
The more recent 
package leaflets were 
lengthier and comprised 
a higher proportion of 
difficult words
Simplification of the 
package leaflets, such 
as useful information 
to patients
Knapp P et al,3 2008
(brief communication)
Presentation of ADR 50 Package leaflets
Presentation of ADR: 
characterization and 
evaluation
20 (40.0%) of the 
package leaflets gave 
no indication of the 
likelihood of the ADR
26 (42.0%) package 
leaflets included verbal 
descriptors, such as the 
general designation 
“common”
4 (8.0%) included data 
of frequency
In the majority of the 
cases ADR were not 
adequately presented
Continue
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Continuation
Pinero-Lopez MA et 
al,23 2011
(abstract)
Evaluation of text-
readability
Package leaflets of 
biopharmaceutical 
medicines
Formulas: SMOG and 
Flesch
40 package leaflets
Readability index: low 
(both formulas)
Most difficult section: 
ADR
Simplification of the 
package leaflets
Roskos SE et al,24 
2008
Evaluation of text-
readability
7 package leaflets of 
nasal steroids
Formula of Fry
The size of letter and 
illustrations size were 
evaluated
On average, the 
package leaflets 
were classified as 
appropriate to people 
with seven years of 
schooling (instead 
of the five years 
recommended)
Letter size: 9 instead 
of 11 (or the minimum 
recommended size)
Only three pictures in 
the package leaflets
Readability problems 
were identified
Wallace et al,27 2007 Adequacy of texts 83 sample of tablets 
+ package leaflets 
(hospital)
Formula of Fry
Letter size
Package leaflets: only 
in 19 samples
The package leaflets 
were classified 
as appropriate to 
people with 10 
years of schooling 
(formula values)
Ideally, samples 
should contain 
package leaflets
Simplification of the 
package leaflets
Zite NB et al,30 2008 Characteristics of texts 8 package leaflets 
(contraceptive).
Formula of 
Gobbledygook
“User-Friendliness 
Toll” to evaluate: 
layout, graphical 
aspects and clarity of 
information
The package leaflets 
were classified 
as appropriate to 
people with 10 
years of schooling 
(formula values)
It was found dosage 
issues and different 
explanations 
on the ideal 
contraceptive effect
Simplification of 
the package leaflets 
(review of texts)
Cavaco A et al,4 2010 Evaluation of text-
readability
4 package leaflets
Translation: 
Portuguese to English
Formulas of SMOG 
and Flesch-kincaid 
(English translations)
The package leaflets 
were classified as 
appropriate to people 
with 10 years of 
schooling (formula 
values)
Correlation of 
Spearman between 
the results: high
Simplification of 
the package leaflets 
for less-educated 
people (adjustment/
adaptation)
ADR: Adverse drug reactions; SMOG: Formula of Simple Measure of Gobbledygook 
of education, instead of the five years recommended 
by Food and Drug Administration);s omission of 
relevant technical information (e.g., maximum daily 
dose,3,4,13,23,24,27,28,30 extensive use of technical words13 
or small letters (e.g., letters with a font size of < 11;24,27 
and lack of illustrations.24,30
We believe that the lack of readability formulae or 
other alternative linguistic metrics to evaluate texts 
specifically written in Portuguese7,9,10,15,16 constitutes 
a limitation. The legibility concepts developed in 
the 1920s and have been continued by writers such 
as Rudolf Flesch,10 George Klare,16 Edgar Dale, and 
Jeanne Chall.7 The Gunning formula (1935)15 was 
one of the first, and according to the equation of this 
formula (suitable for English texts), the education level 
is equal to 0.4*(average size of phrases in number of 
words + the number of words with more than two sylla-
bles per 100 words).9 There are currently several legi-
bility formulas for diverse languages, such as Spanish, 
French, German, Swedish, Russian, Hebrew, Hindi, 
s Food and Drug Administration: Guidance for Industry – Label comprehension studies for Nonprescription Drug Products; 2014 [cited 2010 
Dec 2]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm143834.pdf
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Chinese, Vietnamese, and Korean.9 However, it is not 
known if legibility formulas specifically developed 
for the Portuguese language exist. Similar to other 
languages, Portuguese presents a specific combination 
of linguistic characteristics; thus, the development of 
legibility formulae specifically developed to evaluate 
the readability of Portuguese texts is recommended.4
In some studies, it was not possible to cross-check the 
results of different formulae (double verification)24,28,30 
due to the fact that only one legibility formula was used.
Summary of the methodological limitations
In the studies of this review, the principal limitations 
identified are listed:
1. The inclusion of a limited number of patients 
or health professional in the readability and/or 
usability studies, particularly in the non-confir-
matory studies;1,5,6,8,11,19,21,22,25,26
2. The lack of certain evaluations before the study, 
such as the evaluation of the participants’ cognitive 
state, humor, satisfaction in participating in the test 
or opinion on the use of medicines and their pack-
age leaflets. These factors are likely to influence the 
interpretation of the results (interpretation bias);8
3. In majority of cases, participant literacy was also 
not evaluated, which probably influenced the accu-
racy of the study conclusions;14
4. The non-use of the original packages of medi-
cines or the absence of questions based on imagi-
nary scenarios in several readability and/or usabil-
ity tests, probably also influenced the accuracy of 
data collection;21
5. The illustrations were scarcely used, namely pic-
tograms,10 despite these graphic elements favor-
ing the readability;
6. The selection of packages leaflets based on the 
composition of the medicines, (type of active ingre-
dients)1,6,19,26 may influence their selection (selec-
tion bias) because in general, the package leaflets 
with the worst linguistic characteristics were not 
selected, such as the longer package leaflets or the 
those containing more sentences per paragraph, 
abbreviations, or acronyms;
7. Few studies on patient comprehension of ADR3,17,26 
and absence of studies on patient comprehension 
of specific topics, such as precautions, interactions, 
and contraindications;
8. The nonexistence of multicenter studies to study 
intra- and intercultural differences, such as dia-
lectal differences;
9. The absence of longitudinal studies to investigate 
possible alterations over time, such as those caused 
by social changes, alterations on the pharmaceutical 
regulation or the appearance of new therapeutics;
10. Studies using only one legibility formula, which 
does not allow the comparison of different metrics. 
However, the results obtained through the appli-
cation of legibility formulas are highly correlated 
according to some studies;9
11. The lack of legibility formulae for Portuguese to 
calculate indicators on the simplicity of texts, sim-
ilarly to the legibility formulas of other languages, 
such as English (e.g., Flesch formula).
Because of these methodological limitations, it is 
possible that the studied package leaflets were not 
accurately evaluated.
CONCLUSIONS
The studies on the readability of the package leaflets 
should be based on technical principles and be highly 
suitable with high quality scientific standards. Several 
points are strongly recommended for improving and 
standardizing the readability of package leaflets. 
These include minimizing or avoiding the previously 
discussed limitations, using larger and more varied 
samples of package leaflets, enrolling more participants, 
and development of new metrics and legibility formulas 
for specific languages (e.g., Portuguese).
In this review, diverse factors related with the read-
ability of the package leaflets were highlighted (e.g., 
clear information, simple terms, and package leaflets 
with a proper design. The main methods for ensuring 
the intelligibility and comprehension of the package 
leaflets were the usability tests and the application of 
formulae and/or metrics to their texts.
The encountered readability/usability tests rely on the 
involvement of patients using the medication to test and 
confirm the readability of the informative materials. 
Ideally, these tests should also include patients with 
low literacy levels and health professionals to ensure 
the collection of reliable and efficient results.
The diverse methodological limitations identified 
should be avoided in future studies and considered in 
the assessment of results.
In general, the investigations on the readability of the 
package leaflets and their methods need more scien-
tific contributions to assure the accuracy, reliability, 
and appropriateness of results in the social context and 
language of each country.
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